CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Turkey

  • ID: 2897285
  • Report
  • Region: Turkey
  • 243 pages
  • GlobalData
1 of 5
CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Turkey

Summary

We have released Our latest report “CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Turkey”. The report is an essential source of information on and analysis of the healthcare, regulatory and reimbursement landscape in Turkey. It identifies the key trends in the country’s healthcare market and provides insights into its demographic, regulatory, and reimbursement landscape and healthcare infrastructure. Most importantly, the report provides valuable insights into the trends and segmentation of its pharmaceutical and medical device markets. It uses data and information sourced from proprietary databases, secondary research, and in-house analysis by our team of industry experts.

Turkey’s population stood at approximately 78.74 million in 2015, and is increasing due to a positive balance between the birth and the death rates, as well as longer life expetancy. The pharmaceutical market was estimated at $4.91 billion in 2015, and is expected to reach approximately $5.43 billion by 2020 at a Compound Annual Growth Rate (CAGR) of 2% due to health transformation Program. The medical devices market was estimated approximately $1.59 billion in 2015 and is expected to reach $2.05 billion by 2020, at a CAGR of 4.2%.

The increase in Turkey's phamraceutical market can primarily be attribtued to -
- Improved medical access
- Decline in average price level of the pharmaceuticals
- Increase in the number of pharmaceutical companies

Scope

The report provides information on Turkey’s healthcare, regulatory and reimbursement landscape, and includes -
- An overview of the pharmaceutical and medical devices markets, comprising size, segmentation and key drivers and barriers
- Profiles and SWOT analyses of the major players in the pharmaceutical and medical devices market. The major players covered for the pharmaceutical market are Abdi Ibrahim, Novartis, Pfizer, Sanofi and Bayer. The major players covered for the medical devices market are Baxter, Alcon, Essilor, Fresenius Medical Care and Johnson & Johnson Vision care
- An insightful review of the country’s reimbursement and regulatory landscape, including details of the healthcare reimbursement process, regulatory agencies and approval processes for new drugs
- Detailed analysis of the political and economic environment, including economic indicators, demographics, and healthcare infrastructure and expenditure
- An overview of the opportunities for and challenges to growth in the healthcare market

Reasons to buy

This report will enhance your decision-making capability by allowing you to -
- Develop business strategies by understanding the trends shaping and driving Turkey’s healthcare market
- Drive revenues by understanding the key trends, reimbursement and regulatory policies, pharmaceutical market segments and companies likely to impact Turkey’s healthcare market in the future
- Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing competitors’ performance
- Organize your sales and marketing efforts by identifying the market categories and segments that present the most opportunities for consolidation, investment and strategic partnership
READ MORE
Note: Product cover images may vary from those shown
2 of 5
1.1 List of Tables

1.2 List of Figures

2 Introduction

3 Overview of Pharmaceutical and Medical Device Markets

3.1 Pharmaceutical Market

3.1.1 Market Overview

3.1.2 Pharmaceutical Import and Export

3.1.3 Supply Channels

3.1.4 Market Segments

3.1.5 Major Therapeutic Areas

3.1.6 Major Companies

3.2 Medical Device Market

3.2.1 Market Overview

3.2.2 Overview of Top Five Segments

3.2.3 Major Players

3.3 Market Drivers and Barriers

3.3.1 Drivers

3.3.2 Barriers

4 Market Access

4.1 Reimbursement and Payer Landscape

4.1.1 Overview of Healthcare System

4.1.2 Reimbursement Process

4.1.3 Overview of Insurance Providers

4.1.4 Patient Share of Healthcare Expenditure

4.1.5 Healthcare Price Trends

4.1.6 Pricing Policies

4.2 Regulatory Landscape

4.2.1 Overview of Regulatory Agencies

4.2.2 Market Authorization Procedure for Pharmaceutical Products

4.2.3 New Medical Device Approval Process

4.2.4 Licensing Process for Pharmaceutical and Medical Device Manufacturing

4.2.5 Licensing Process for Pharmaceutical Exports and Imports

4.2.6 Intellectual Property Rights

4.2.7 Clinical Trial Regulations

4.2.8 Pharmaceutical Advertising Regulations

4.2.9 Pharmacy Regulations

4.2.10 Labeling and Packaging Regulations

5 Country Analysis

5.1 Political Environment

5.1.1 Political Structure

5.1.2 Analysis of the Current Political Environment

5.1.3 Healthcare Policy Initiatives

5.2 Economic Landscape

5.3 Economic Indicators

5.3.1 Gross Domestic Product

5.3.2 Gross National Income

5.3.3 Inflation

5.3.4 Currency Exchange Rate

5.3.5 Foreign Direct Investment

5.3.6 Foreign Exchange Reserves

5.3.7 Trade Balance

5.3.8 Government Structural Balance

5.3.9 Government Net Debt

5.3.10 Major Industries

5.4 Demographics

5.4.1 Population

5.4.2 Education and Literacy

5.4.3 Employment

5.4.4 Disease Burden

5.5 Healthcare Infrastructure

5.5.2 Healthcare Parameters

5.5.3 Environmental Health

5.5.4 Healthcare Personnel

5.6 Healthcare Expenditure

5.6.1 Overview of Healthcare Expenditure

5.6.2 Major Components of Healthcare Expenditure

5.6.3 Healthcare Expenditure Distribution

5.6.4 Spending in Pharmaceutical R&D

5.7 Trade Associations

5.7.1 Turkish Pharmacists’ Association

5.7.2 Pharmaceutical Manufacturer’s Association of Turkey

5.7.3 Turkish Confederation of Employer Associations

5.8 Trade Fairs

6 Opportunities and Challenges

6.1 Opportunities

6.2 Challenges

7 Appendix

7.1 Abbreviations

7.2 Bibliography

7.3 Research Methodology

7.3.1 Coverage

7.3.2 Secondary Research

7.3.3 Forecasts

7.3.4 Expert Panel

7.4 Disclaimer

1.1 List of Tables

Table 1: Pharmaceutical Market, Turkey, Revenue ($bn), 2008-2015

Table 2: Pharmaceutical Market, Turkey, Revenue ($bn), 2016-2020

Table 3: Pharmaceutical Market, Turkey, Imports and Exports ($bn), 2008-2015

Table 4: Generic Market, Turkey, Revenue ($bn), 2008-2015

Table 5: OTC Market, Turkey, Revenue ($bn), 2008-2015

Table 6: Pharmaceutical Market, Turkey, Major Therapeutic Areas by Value (%), 2015

Table 7: Pharmaceutical Market, Abdi Ibrahim, Major Products, 2016

Table 8: Pharmaceutical Market, Novartis, Major Products, 2016

Table 9: Pharmaceutical Market, Novartis, Global, Planned Filings, 2015

Table 10: Pharmaceutical Market, Pfizer, Global, Major Products, 2015

Table 11: Pharmaceutical Market, Pfizer, Global, Planned Filings, 2015

Table 12: Pharmaceutical Market, Sanofi, Global, Planned Filings, 2015

Table 13: Pharmaceutical Market, Bayer, Major Marketed Products, 2015

Table 14: Pharmaceutical Market, Bayer, Pipeline Products, 2015

Table 15: Medical Device Market, Turkey, Revenue ($bn), 2008-2015

Table 16: Medical Device Market, Turkey, Revenue ($bn), 2016-2020

Table 17: Medical Device Market, Turkey, Major Players by Revenue ($m) and Share (%), 2015

Table 18: Ophthalmic Device Market, Turkey, Revenue ($m), 2008-2015

Table 19: Ophthalmic Device Market, Turkey, Major Players by Revenue ($m) and Market Share (%), 2012

Table 20: Nephrology and Urology Diagnostics Device Market, Turkey, Revenue ($m), 2008-2015

Table 21: Nephrology and Urology Diagnostics Device Market, Turkey, Major Players by Revenue ($m) and Share (%), 2012

Table 22: Orthopedic Device Market, Turkey, Revenue ($m), 2008-2015

Table 23: Orthopedics Device Market, Turkey, Major Players by Revenue ($m) and Share (%), 2015

Table 24: Drug Delivery Device Market, Turkey, Revenue ($m), 2008-2015

Table 25: Drug Delivery Device Market, Turkey, Major Players by Revenue ($m) and Share (%), 2012

Table 26: Diabetes Care Device Market, Turkey, Revenue ($m), 2008-2015

Table 27: Diabetes Care Device Market, Turkey, Major Players by Revenue ($m) and Share (%), 2012

Table 28: Medical Device Market, Turkey, Revenue by Leading Companies ($m), 2012

Table 29: Baxter, Global, Major Products, 2016

Table 30: Major Products, Alcon, Major Products, 2015

Table 31: Fresenius Medical Care, Major Products, 2015

Table 32: Johnson & Johnson, Global, Major Products, 2016

Table 33: Healthcare Spending, Turkey, Patient Share (%), 2008-2015

Table 34: Healthcare Industry, Turkey, Price Change (%), 2008-2014

Table 35: Economic Indicators, Turkey, Gross Domestic Product per Capita ($), 2008-2015

Table 36: Economic Indicators, Turkey, Gross Domestic Product per Capita ($), 2016-2020

Table 37: Economic Indicators, Turkey, Gross Domestic Product Annual Growth (%), 2008-2015

Table 38: Economic Indicators, Turkey, Gross Domestic Product Annual Growth (%), 2016-2020

Table 39: Economic Indicators, Turkey, Gross National Income per Capita ($), 2008-2014

Table 40: Economic Indicators, Turkey, Consumer Price Index, 2008-2015

Table 41: Economic Indicators, Turkey, Consumer Price Index, 2016-2020

Table 42: Economic Indicators, Turkey, Average Annual Consumer Price Change (%), 2008-2015

Table 43: Economic Indicators, Turkey, Average Annual Consumer Price Change (%), 2016-2020

Table 44: Economic Indicators, Turkey, Currency Exchange Rate (TL/$), 2008-2015

Table 45: Economic Indicators, Turkey, Foreign Direct Investment ($bn), 2008-2014

Table 46: Economic Indicators, Turkey, Foreign Exchange Reserves ($bn), 2008-2014

Table 47: Economic Indicators, Turkey, Imports ($bn), 2008-2014

Table 48: Economic Indicators, Turkey, Exports ($bn), 2008-2014

Table 49: Economic Indicators, Turkey, Government Structural Balance ($bn), 2008-2015

Table 50: Economic Indicators, Turkey, Government Net Debt ($bn), 2008-2015

Table 51: Economic Indicators, Turkey, Government Net Debt ($bn), 2016-2020

Table 52: Economic Indicators, Turkey, Major Industries by Hours Worked Index, 2014

Table 53: Demographics, Turkey, Population (million), 2008-2015

Table 54: Demographics, Turkey, Population (million), 2016-2020

Table 55: Demographics, Turkey, Urban-Rural Population Share (%), 2008-2015

Table 56: Demographics, Turkey, Urban-Rural Population Share (%), 2016-2020

Table 57: Demographics, Turkey, Population Distribution by Age Group (%), 2008-2015

Table 58: Demographics, Turkey, Population Distribution by Age Group (%), 2016-2020

Table 59: Demographics, Turkey, Births (per 1,000 population), 2008-2015

Table 60: Demographics, Turkey, Mortality (per 1,000 population), 2008-2015

Table 61: Demographics, Turkey, Causes of Mortality (%), 2015

Table 62: Demographics, Turkey, Infant Mortality Rate (per 1,000 live births), 2008-2015

Table 63: Demographics, Turkey, Immunization Rate (%), 2008-2015

Table 64: Demographics, Turkey, Male Mortality Rate (%), 2014

Table 65: Demographics, Turkey, Female Mortality Rate (%), 2014

Table 66: Demographics, Turkey, Gender Ratio (M/F), 2008-2014

Table 67: Demographics, Turkey, Life Expectancy at Birth (years), 2008-2015

Table 68: Demographics, Turkey, Literacy by Age Group (%), 2014

Table 69: Demographics, Turkey, Unemployment Rate (%), 2008-2015

Table 70: Demographics, Turkey, Disability-Adjusted Life Years (per 1,000 population), 2009

Table 71: Healthcare Infrastructure, Turkey, Public and Private Hospitals, 2008-2015

Table 72: Healthcare Infrastructure, Turkey, Diagnostic Units (per 100,000 population), 2008-2015

Table 73: Healthcare Infrastructure, Turkey, Beds (per 1,000 population), 2008-2015

Table 74: Healthcare Parameters, Turkey, Beds by Type of Care (per 1,000 population), 2008-2015

Table 75: Healthcare Infrastructure, Turkey, Doctors (per 1,000 population), 2008-2015

Table 76: Demographics, Turkey, Water Pollution Sources (thousand m3/year), 2014

Table 77: Environmental Health, Turkey, CO2 Emissions (million tons), 2008-2015

Table 78: Environmental Health, Turkey, NOx Emissions (thousand tons), 2008-2015

Table 79: Environmental Health, Turkey, SOx Emissions (thousand tons), 2008-2015

Table 80: Environmental Health, Turkey, PM2.5 Emissions (µg/m3), 2008-2015

Table 81: Healthcare Personnel, Turkey, Nurses (per 100,000 population), 2008-2015

Table 82: Healthcare Personnel, Turkey, Pharmacists (per 100,000 population), 2008-2015

Table 83: Healthcare Personnel, Turkey, Dentists (per 100,000 population), 2008-2015

Table 84: Healthcare Expenditure, Turkey, Healthcare Expenditure (% of GDP), 2008-2015

Table 85: Healthcare Expenditure, Turkey, Share of Major Components (%), 2014

Table 86: Healthcare Expenditure, Turkey, Public-Private Share of Healthcare Expenditure ($ per capita), 2008-2015

Table 87: Healthcare Expenditure, Turkey, Public-Private Share of Healthcare Expenditure (% of GDP), 2008-2015

Table 88: Major Healthcare Trade Fairs, Turkey, 2016-2017

1.2 List of Figures

Figure 1: Pharmaceutical Market, Turkey, Revenue ($bn), 2008-2015

Figure 2: Pharmaceutical Market, Turkey, Revenue ($bn), 2016-2020

Figure 3: Pharmaceutical Market, Turkey, Imports and Exports ($bn), 2008-2015

Figure 4: Generic Market, Turkey, Revenue ($bn), 2008-2015

Figure 5: OTC Market, Turkey, Revenue ($bn), 2008-2015

Figure 6: Pharmaceutical Market, Turkey, Major Therapeutic Areas by Value (%), 2015

Figure 7: Medical Device Market, Turkey, Revenue ($bn), 2008-2015

Figure 8: Medical Device Market, Turkey, Revenue ($bn), 2016-2020

Figure 9: Medical Device Market, Turkey, Revenue by Segment ($m), 2015

Figure 10: Ophthalmic Device Market, Turkey, Revenue ($m), 2008-2015

Figure 11: Ophthalmic Device Market, Turkey, Major Players by Share (%), 2012

Figure 12: Nephrology and Urology Diagnostics Device Market, Turkey, Revenue ($m), 2008-2015

Figure 13: Nephrology and Urology Diagnostics Device Market, Turkey, Major Players by Share (%), 2012

Figure 14: Orthopedic Device Market, Turkey, Revenue ($m), 2008-2015

Figure 15: Orthopedics Device Market, Turkey, Major Players by Share (%), 2015

Figure 16: Drug Delivery Device Market, Turkey, Revenue ($m), 2008-2015

Figure 17: Drug Delivery Device Market, Turkey, Major Players by Share (%), 2012

Figure 18: Diabetes Care Device Market, Turkey, Revenue ($m), 2008-2015

Figure 19: Diabetes Care Device Market, Turkey, Major Players by Share (%), 2012

Figure 20: Medical Device Market, Turkey, Revenue by Leading Companies ($m), 2012

Figure 21: Healthcare Market, Turkey, Drivers and Barriers, 2016

Figure 22: Chronology of the Republican Era of Medicine and Pharmacy Management, Turkey, 2016

Figure 23: Strategic Planning Management, Turkey, 2016

Figure 24: Organizational Structure of Ministry of Health, Turkey, 2016

Figure 25: Drug Reimbursement Approval Process, Turkey, 2015

Figure 26: Healthcare Spending, Turkey, Patient Share (%), 2008-2015

Figure 27: Healthcare Industry, Turkey, Price Change (%), 2008-2014

Figure 28: Organizational Structure of Ministry of Health, Turkey, 2016

Figure 29: Major Health Reforms, Turkey, 2008-2015

Figure 30: Economic Indicators, Turkey, Gross Domestic Product per Capita ($), 2008-2015

Figure 31: Economic Indicators, Turkey, Gross Domestic Product per Capita ($), 2016-2020

Figure 32: Economic Indicators, Turkey, Gross Domestic Product Annual Growth (%), 2008-2015

Figure 33: Economic Indicators, Turkey, Gross Domestic Product Annual Growth (%), 2016-2020

Figure 34: Economic Indicators, Turkey, Gross National Income per Capita ($), 2008-2014

Figure 35: Economic Indicators, Turkey, Consumer Price Index, 2008-2015

Figure 36: Economic Indicators, Turkey, Consumer Price Index, 2016-2020

Figure 37: Economic Indicators, Turkey, Average Annual Consumer Price Change (%), 2008-2015

Figure 38: Economic Indicators, Turkey, Average Annual Consumer Price Change (%), 2016-2020

Figure 39: Economic Indicators, Turkey, Currency Exchange Rate (TL/$), 2008-2015

Figure 40: Economic Indicators, Turkey, Foreign Direct Investment ($bn), 2008-2014

Figure 41: Economic Indicators, Turkey, Foreign Exchange Reserves ($bn), 2008-2014

Figure 42: Economic Indicators, Turkey, Imports ($bn), 2008-2014

Figure 43: Economic Indicators, Turkey, Exports ($bn), 2008-2014

Figure 44: Economic Indicators, Turkey, Government Structural Balance ($bn), 2008-2015

Figure 45: Economic Indicators, Turkey, Government Net Debt ($bn), 2008-2015

Figure 46: Economic Indicators, Turkey, Government Net Debt ($bn), 2016-2020

Figure 47: Economic Indicators, Turkey, Major Industries by Hours Worked Index, 2014

Figure 48: Demographics, Turkey, Population (million), 2008-2015

Figure 49: Demographics, Turkey, Population (million), 2016-2020

Figure 50: Demographics, Turkey, Urban-Rural Population Share (%), 2008-2015

Figure 51: Demographics, Turkey, Urban-Rural Population Share (%), 2016-2020

Figure 52: Demographics, Turkey, Population Distribution by Age Group (%), 2008-2015

Figure 53: Demographics, Turkey, Population Distribution by Age Group (%), 2016-2020

Figure 54: Demographics, Turkey, Births (per 1,000 population), 2008-2015

Figure 55: Demographics, Turkey, Mortality (per 1,000 population), 2008-2015

Figure 56: Demographics, Turkey, Causes of Mortality (%), 2015

Figure 57: Demographics, Turkey, Infant Mortality Rate (per 1,000 live births), 2008-2015

Figure 58: Demographics, Turkey, Immunization Rate (%), 2008-2015

Figure 59: Demographics, Turkey, Male Mortality Rate (%), 2014

Figure 60: Demographics, Turkey, Female Mortality Rate (%), 2014

Figure 61: Demographics, Turkey, Gender Ratio (M/F), 2008-2015

Figure 62: Demographics, Turkey, Life Expectancy at Birth (years), 2008-2015

Figure 63: Demographics, Turkey, Literacy by Age Group (%), 2014

Figure 64: Demographics, Turkey, Unemployment Rate (%), 2008-2015

Figure 65: Demographics, Turkey, Disability-Adjusted Life Years (per 1,000 population), 2009

Figure 66: Healthcare Infrastructure, Turkey, Public and Private Hospitals, 2008-2015

Figure 67: Healthcare Infrastructure, Turkey, Diagnostic Units (per 100,000 population), 2008-2015

Figure 68: Healthcare Infrastructure, Turkey, Beds (per 1,000 population), 2008-2015

Figure 69: Healthcare Parameters, Turkey, Beds by Type of Care (per 1,000 population), 2008-2015

Figure 70: Healthcare Infrastructure, Turkey, Doctors (per 1,000 population), 2008-2015

Figure 71: Demographics, Turkey, Sources of Water Pollution (thousand m3/year), 2014

Figure 72: Environmental Health, Turkey, CO2 Emissions (million tons), 2008-2015

Figure 73: Environmental Health, Turkey, NOx Emissions (thousand tons), 2008-2015

Figure 74: Environmental Health, Turkey, SOx Emissions (thousand tons), 2008-2015

Figure 75: Environmental Health, Turkey, PM2.5 Emissions (µg/m3), 2008-2015

Figure 76: Healthcare Personnel, Turkey, Nurses (per 100,000 population), 2008-2015

Figure 77: Healthcare Personnel, Turkey, Pharmacists (per 100,000 population), 2008-2015

Figure 78: Healthcare Personnel, Turkey, Dentists (per 100,000 population), 2008-2015

Figure 79: Healthcare Expenditure, Turkey, Healthcare Expenditure (% of GDP), 2008-2015

Figure 80: Healthcare Expenditure, Turkey, Share of Major Components (%), 2014

Figure 81: Healthcare Expenditure, Turkey, Public-Private Share of Healthcare Expenditure ($ per capita), 2008-2015

Figure 82: Healthcare Expenditure, Turkey, Pharmaceutical R&D Expenditure (% of GDP), 2008-2015

Figure 83: Healthcare Market, Turkey, Opportunities and Challenges, 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
Growing prevalence of chronic ailments, medical tourism, universal health coverage and healthcare reforms are boosting healthcare market growth, although a reduction in the price of medicines through discounts and increasing generic consumption is a major challenge

In 2012, the pharmaceutical market was worth approximately $12.5 billion and was the sixth-largest pharmaceutical market in Europe. It is set to grow at a Compound Annual Growth Rate (CAGR) of 7.3% from 2008 to reach $21.5 billion in 2020 (MoE, 2014; ISPAT, 2012).

The population in 2013 was approximately 76.7 million, having grown at a CAGR of 1.4% from 2008. As is the case with many developed countries, the elderly population is increasing in size and as of 2013 comprised 7.7% of the entire population. The prevalence of non-communicable diseases, such as cardiovascular disease, respiratory disease, metabolic disorder and cancer, has increased due to an increasingly sedentary way of life.

An industrial revival began in 1952, after which production began to increase with the establishment of domestic and internationally owned plants. In 1984, Good Manufacturing Practice (GMP) was introduced, and quality control guidelines for the production of foods, pharmaceutical products, and medical devices were improved as a result. The market has expanded steadily since 1952 (MoE, 2012). As of 2012, there were 94 pharmaceutical production facilities, of which 17 were multi-national companies and 18 were raw-material-producing facilities (IEIS, 2012b).

The healthcare system has entered a long period of development under the Health Transformation Program (Saglikta Donus, um Programi, HTP) 2002–2013. The implementation of the HTP resulted in social security reforms aimed at improving universal health coverage. The pharmaceutical market is also driven by a national health insurance system. In 2013, 62.8 million people were covered under government health insurance (Sosyal Guvenlik Kurumu, SGK) (SGK, 2014).

The available infrastructure for healthcare industries and the high number of healthcare institutions makes Turkey an attractive location for the manufacture and marketing of pharmaceutical products. Medical tourism is another driving factor of the pharmaceutical industry. In 2012, Turkey received 270,000 foreign patients. Services for medical tourism are primarily provided by private hospitals, and the government provides tax exemptions for private hospitals, to encourage medical tourism (MoH, 2012c).

The government is also trying to increase pharmaceutical R&D. In 2012, it introduced a new investment incentives program, which has four basic schemes for increasing foreign investment. There are 150 R&D centers in Turkey, and in April 2013 Dupont opened its 11th innovation center (ISPAT, 2013a).

The price of medicine is very low, compared with other EU countries (AiFD, 2007). Turkey uses a reference pricing system in combination with discounts for the sale of its pharmaceuticals. In 2009, to curb changes in the price of medicine, the government fixed the euro to the lira conversion rate (Bilmen, 2014). These factors greatly reduce the profit margin for pharmaceutical companies, making pricing a major challenge for the growth of the pharmaceutical market. In addition, the use of generics is high: in 2012, 53% of the drugs consumed were generics (MoH, 2012). The usage of generics is expected to grow and thus mitigate the growth of the market.

There is a large market for medical devices due to the growing elderly population and subsequent increase in demand for healthcare products and services. The medical device market was valued at approximately $1.9 billion in 2008 and is estimated to grow at a CAGR of 4.7% to reach $3.3 billion in 2020. Turkey predominantly depends on imports for its medical devices, as many of its domestic producers are involved with products that do not require high technology.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll